Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism

Sorafenib is used as first line treatment of renal cell carcinoma (RCC) due to the poor sensitivity to radiotherapy and chemotherapy of this malignancy; however, acquired resistance limits the application of sorafenib and its analogues. In this study, we explored a new strategy to overcome acquired...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuai, Gao, Mingwei, Wang, Xiaoqing, Ding, Sentai, Lv, Jiaju, Gao, Dexuan, Wang, Zhiyang, Niu, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346704/
https://www.ncbi.nlm.nih.gov/pubmed/27816967
http://dx.doi.org/10.18632/oncotarget.13003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346704/
https://www.ncbi.nlm.nih.gov/pubmed/27816967
http://dx.doi.org/10.18632/oncotarget.13003

Ejemplares similares